Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy.

Arendt Nielsen T, Sega R, Uggerhøj Andersen C, Vorum H, Drewes AM, Jakobsen PE, Brock B, Brock C

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics16 Dec 2021Cited by 3 (Europe PMC)

PMID34918951DOI10.1089/jop.2021.0055PepBankPUB-34918951

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, neuropathy and retinopathy, liraglutide did not change mean peripapillary retinal nerve fibre layer thickness versus placebo (-1 μm in both groups).
In plain wordsIn adults with type 1 diabetes, liraglutide did not change the thickness of a retinal nerve layer compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeChange in mean peripapillary RNFL thickness, overall
Study
n = 37
Comparator
Placebo
Analysis
Primary
Outcome group
Neuroprotection · Eye
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
ΔMean RNFL thickness
−1 μm
liraglutide
ΔMean RNFL thickness
−1 μm
placebo
Source sentences
Summary
No differences in mean peripapillary RNFL thickness (overall ΔMean RNFL thickness; liraglutide -1 (±8) μm (-1%) vs. placebo -1 (±5) μm (-1%), P = 0.78, n = 37)
2 context sentences(design, population, supporting numbers)
Summary · context
The primary endpoint was a change in peripapillary RNFL thickness between treatments, assessed by optical coherence tomography.
Summary · context
Secondary analyses were performed on a prospective, double-blinded, randomized, placebo-controlled trial on adults with type 1 diabetes, distal symmetric polyneuropathy (DSPN), and confirmed diabetic retinopathy, who were randomized 1:1 to either 26 weeks placebo or liraglutide treatment.
Report a problemFND-3491895101
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, neuropathy and retinopathy, liraglutide did not change peripapillary RNFL thickness in any quadrant versus placebo.
In plain wordsIn adults with type 1 diabetes, liraglutide did not change retinal nerve layer thickness in any area compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeChange in peripapillary RNFL thickness by quadrant
Study
n = 37
Comparator
Placebo
Outcome group
Neuroprotection · Eye
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
or any of the quadrants.
1 context sentence(design, population, supporting numbers)
Summary · context
Secondary analyses were performed on a prospective, double-blinded, randomized, placebo-controlled trial on adults with type 1 diabetes, distal symmetric polyneuropathy (DSPN), and confirmed diabetic retinopathy, who were randomized 1:1 to either 26 weeks placebo or liraglutide treatment.
Report a problemFND-3491895102
03HumanRandomized controlled trialEfficacy outcome
In adults with nonproliferative diabetic retinopathy, liraglutide did not change mean RNFL thickness versus placebo.
In plain wordsIn adults with early diabetic eye disease, liraglutide did not change retinal nerve layer thickness compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeChange in mean RNFL thickness, nonproliferative retinopathy subgroup
Study
n = 26
Comparator
Placebo
Outcome group
Neuroprotection · Eye
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
ΔMean RNFL thickness
−1 μm
liraglutide, nonproliferative
ΔMean RNFL thickness
0 μm
placebo, nonproliferative
Source sentences
Summary
nonproliferative (ΔMean RNFL thickness; liraglutide -1 (±5) μm (-1%) vs. placebo 0 (±4) μm (0%), P = 0.80, N = 26)
1 context sentence(design, population, supporting numbers)
Summary · context
Secondary analyses were performed on a prospective, double-blinded, randomized, placebo-controlled trial on adults with type 1 diabetes, distal symmetric polyneuropathy (DSPN), and confirmed diabetic retinopathy, who were randomized 1:1 to either 26 weeks placebo or liraglutide treatment.
Report a problemFND-3491895103
04HumanRandomized controlled trialEfficacy outcome
In adults with proliferative diabetic retinopathy, liraglutide did not change mean RNFL thickness versus placebo.
In plain wordsIn adults with advanced diabetic eye disease, liraglutide did not change retinal nerve layer thickness compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeChange in mean RNFL thickness, proliferative retinopathy subgroup
Study
n = 11
Comparator
Placebo
Outcome group
Neuroprotection · Eye
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Measurements
ΔMean RNFL thickness
−2 μm
liraglutide, proliferative
ΔMean RNFL thickness
−1 μm
placebo, proliferative
Source sentences
Summary
proliferative diabetic retinopathy subgroup (ΔMean RNFL thickness; liraglutide -2 (±14) μm (-3%) vs. placebo -1 (±6) μm (-2%), P = 0.88, N = 11)
1 context sentence(design, population, supporting numbers)
Summary · context
Secondary analyses were performed on a prospective, double-blinded, randomized, placebo-controlled trial on adults with type 1 diabetes, distal symmetric polyneuropathy (DSPN), and confirmed diabetic retinopathy, who were randomized 1:1 to either 26 weeks placebo or liraglutide treatment.
Report a problemFND-3491895104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT02138045

Treatment of Diabetic Neuropathy With Liraglutide

Aalborg University Hospitaln = 39May 2014 to Feb 2017

Diabetes Mellitus, Type 1 · Type 1 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 10 Aug 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.